Recombinant TcdB anticorps

N° du produit ABIN7566457

Cet anticorps Human Monoclonal détecte spécifiquement TcdB dans ELISA, Func et WB. Il présente une réactivité avec des échantillons de Clostridium difficile.

Aperçu rapide pour Recombinant TcdB anticorps (ABIN7566457)

Antigène: TcdB

Type d'anticorp: Recombinant Antibody

Reactivité: Clostridium difficile

Hôte: Human

Clonalité: Monoclonal

Application: ELISA, Functional Studies (Func), Western Blotting (WB)

Clone: VIF090-A6

Détail du produit

Fonction: anti-TcdB (Clostridioides difficile extoxin), mAb (rec.) (VIF090-A6)

Attributs du produit:

Recombinant Antibody. Recognizes TcdB from Clostridioides difficile. Applications: ELISA, FUNC, WB. Clone: VIF090-A6. Isotype: Human IgG1. Formulation: Liquid. In PBS. Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.

Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.

Purification: Puified

Pureté: >95 % (SDS-PAGE)

Immunogène: Recombinant TcdB (Clostridioides difficile, strain VPI10463) containing a C-terminal His-tag.

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: In PBS.

Conseil sur la manipulation: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.

Stock: 4 °C,-20 °C

Stockage commentaire:

Stable for at least 1 year after receipt when stored at -20°C.

Stable for at least 1 week when stored at +4°C.

Détail du antigène

Antigène: TcdB

UniProt: Q189K3